UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000004009 |
|---|---|
| Receipt number | R000004818 |
| Scientific Title | Phase I trial of Nedaplatin+5FU+Doc combination therapy for Recurrence or Metastatic of Esophagus cancer |
| Date of disclosure of the study information | 2010/08/06 |
| Last modified on | 2021/02/25 18:09:18 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase I trial of Nedaplatin+5FU+Doc combination therapy for Recurrence or Metastatic of Esophagus cancer
Acronym
Phase I trial of Nedaplatin+5FU+Doc combination therapy for Recurrence or Metastatic of Esophagus cancer
Scientific Title
Phase I trial of Nedaplatin+5FU+Doc combination therapy for Recurrence or Metastatic of Esophagus cancer
Scientific Title:Acronym
Phase I trial of Nedaplatin+5FU+Doc combination therapy for Recurrence or Metastatic of Esophagus cancer
Region
| Japan |
Condition
Condition
Esophagus cancer
Classification by specialty
| Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
We have a recurrence symptom example or distant metastasis and review nedaplatin for the esophageal cancer that radical radiotherapy is impossible and 5FU and decision of a recommendation dosage of Doc medical treatment and influence to give to safety and pharmacokinetics of both medicine.
Furthermore, we put it together and perform examination about antitumor effect of this combination therapy.
Basic objectives2
Safety
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Decision of a recommended dosage
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
2010/6-2013/5
nedaplatin 70-90mg/m2
Doc 30-35mg/m2
5FU 800mg/m2/day
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 75 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1)Primary tumor is either of cervical part / thoracic esophagus.
2)It is diagnosed as either of a squamous cell carcinoma, an adenosquamous carcinoma, adenocarcinoma for histopathology.
3)It is unresectable esophageal cancer or oesophageal carcinoma recurrent, and, at the time of registration, a thing and the unresectable esophageal cancer that an operation, radiotherapy, adaptation of chemoradiotherapy judged not to be it satisfy 1-3 entirely, and oesophageal carcinoma recurrent satisfy 3.
1,Clinical invasion depth is cT1-cT4.
2,Distant metastasis falls under following neither.
i)Distant metastasis part is only a cervical lymph node.
ii)Distant metastasis part is only celiac artery circumference lymph gland.
3,It is slightness whether there is not passage disorder, and ingestion is capable enough.
4)ECOG Performance status is 0 or 1.
5)There are not chemotherapies, chemoradiotherapy and a history of radiotherapy for every cancer class including esophageal cancer.
6)We satisfy all the following conditions.
that examination of an equal day two weeks of registration day ago permits it
(1)4,000 white blood corpuscle >= /mm3 and 12,000 <= /mm3
(2)2,000 mature granulocyte >= /mm3
(3)100,000 blood platelet >= /mm3
(4)Haemoglobin >= 9.0g/dL
(5)100 AST <= IU/L
(6)100 ALT <= IU/L
(7)Bilirubin total <= 1.2mg/dL
(8)Creatinine <= 1.5mg/dL
(9)A hepatitis B surface antigen is negative on examination before registration
(10)SpO2 >= 95% (room air)
(11)12 resting inductive electrocardiograms within 28th before registration do not show abnormal findings to need treatment.
7)There are not metastases to brain having a symptom.
8)We do not show the moderate above-mentioned pleural effusion, ascitic fluid.
9)About final examination participation, an agreement by a document from the person himself is obtained.
Key exclusion criteria
1)
During treatment or diabetes mellitus inadequate control (HbA1c merges) doing more than 6.5% with an aim by consecutive use of insulin.
2)
The patient having active multiple primary cancer (synchronism multiple primary cancer and a having sound health period, metachronous multiple primary cancer within five years).
But healing and judged carcinoma in situ (carcinoma in situ) or lesion of intramucosal carcinoma equivalency cannot include.In active multiple primary cancer by local treatment.
3)
It is the patient having an anaphylactic history for DOC, CDGP, 5-FU and polysorbate "80" component pharmaceutical.
4)
We have active bacteria and fungal infection.
(we have pyrexia more than 38 degrees Celsius, and bacterial infection is proved on an imaging or bacteriologic examination)
5)
The patient who has consecutive systemic therapy (in internal use or a vein) of steroid.
6)
Regardless of presence of a cause, it is motor paralysis, the patient having peripheral neuropathy (more than CTCAE v3.0, Grade 1).
7)
The patient who shows dropsy (more than CTCAE v3.0, Grade 1) regardless of presence of cause.
8)
The patient having the interstitial pneumonia that is apparent by chest X-rays or CT or pulmonary fibrosis.
9)
The patient whom we merge psychosis or neurologic manifestation, and it is judged to have difficulty with participation to an examination.
10)
During the pregnancy or a pregnant female patient we are possible or are nursing.
Target sample size
18
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | shinya ueda |
Organization
Kinki University School of Medicine
Division name
Department of Medical Oncology
Zip code
Address
377-2,ohnohigashi,osakasayamashi,osaka
TEL
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name |
Organization
Kinki University School of Medicine
Division name
Department of Medical Oncology
Zip code
Address
TEL
0723660221
Homepage URL
Sponsor or person
Institute
Kinki University School of Medicine
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2010 | Year | 08 | Month | 06 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2010 | Year | 07 | Month | 02 | Day |
Date of IRB
| 2010 | Year | 07 | Month | 02 | Day |
Anticipated trial start date
| 2010 | Year | 07 | Month | 01 | Day |
Last follow-up date
| 2015 | Year | 07 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2010 | Year | 08 | Month | 06 | Day |
Last modified on
| 2021 | Year | 02 | Month | 25 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004818
